NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Our US biotech holdings were also hit hard. The month’s largest detractor was Northwest Biotherapeutics, after rumours that the clinical trial of its DCVax-L oncology treatment had been suspended.

[1.] The company has confirmed that the suspension related simply to the recruitment of new patients and was a temporary measure while regulatory information was submitted, in line with clinical protocols.

[2.] The trial is continuing and we see nothing untoward in this development. Alkermes and Prothena sold off heavily too –

[3.] Again, we have no fundamental grounds for concern and were able to take advantage of the share price weakness.’ September 14, 2015 Neil Woodford

Note: Much has been said about this quote, but I think not all points were emphasized, and though it seems like a long time ago, he discussed this on September 14, 2015.